Capstone Investment Advisors
ADMA icon

Capstone Investment Advisors’s ADMA Biologics ADMA Stock Holding History

Capstone Investment Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$246K Buy
29,341
+18,167
+163% +$166K ﹤0.01% 1539
2026
Q1 		$101K Buy
+11,174
New +$176K ﹤0.01% 1545
2025
Q3 		– Sell
-21,117
Closed -$385K – 1891
2025
Q2 		$385K Buy
+21,117
New +$431K ﹤0.01% 1271
2024
Q2 		– Sell
-16,117
Closed -$106K – 2039
2024
Q1 		$106K Buy
+16,117
New +$88.1K ﹤0.01% 2130

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Capstone Investment Advisors's ADMA Position: Q2 2026 in Review

Capstone Investment Advisors increased its ADMA Biologics (ADMA) stake by 163% in Q2 2026, buying an estimated $166K and bringing the position to 29,341 shares worth $246K. The position accounts for ﹤0.01% of the portfolio, ranked #1539.

Capstone Investment Advisors first reported a position in ADMA in Q1 2024 and has held it in 4 quarters since. The position peaked at $385K in Q2 2025. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Capstone Investment Advisors held 29,341 shares of ADMA Biologics worth $246K as of Q2 2026.
  • Capstone Investment Advisors bought 18,167 ADMA Biologics shares in Q2 2026, an estimated $166K.
  • ADMA Biologics made up ﹤0.01% of Capstone Investment Advisors's portfolio in Q2 2026, its #1539 holding.
  • Capstone Investment Advisors first reported a position in ADMA Biologics in Q1 2024 and has held it in 4 quarters since.
  • Capstone Investment Advisors's ADMA Biologics position peaked at $385K in Q2 2025.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Capstone Investment Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.